The biotechnology company, Owl Genomics, has opened their new head office in building 502 of the Bizkaia Technology Park, thus reinforcing their strategy of expansion. The new head office has a surface area of more than 600 m², with facilities including a spacious hall containing state-of-the-art equipment and a modern laboratory for the preparation of samples. The opening ceremony was attended by the Councillor for Health, Rafael Bengoa.
Owl Genomics is a biotechnology company focussing on human health; it was founded in 2002, with the principal objective of identifying diagnosis markers and therapeutic targets in highly prevalent complex diseases, initially focussing on liver-related disease. With a team headed by Dr Jose María Mato, specialist in hepatic disease, the leading shareholder of the company is the venture capital company, Cross Road Biotech.
Using metabolimics, a new technology combining high-precision liquid chromatography with mass spectrometry, Owl Genomics has selected biomarkers for the diagnosis of steatosis and non-alcoholic steatohepatitis.
Owl Genomics has just reached an exceptional milestone with the launch of the first in-vitro diagnosis method based on metabolimics, named owl liver, which determines the advance of the disease with a simple blood test.